Abstract 1703P
Background
Genome-targeted cancer drug approvals have increased, offering personalized therapy at high cost. We assessed genome-targeted cancer drugs to determine the validity of the targets and clinical benefits identified in the pivotal clinical trials.
Methods
We identified trials FDA-designated as pivotal that supported genome-targeted cancer drug approvals between 2015-2022. From drug labeling and publications, we extracted characteristics of the trials. Strength of evidence supporting molecular targetability was assessed by the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT). Clinical benefit for approved indications was evaluated by the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) with substantial benefit defined as grade A or B for curative and 4 or 5 for noncurative intent. Molecular targets qualifying for ESCAT level I-A and I-B associated with substantial clinical benefit were rated as high benefit.
Results
Among 50 molecular-targeted drugs approved for 84 indications, 45 (54%) were based on phase I/II trials and 45 were supported by single-arm studies. The most common primary endpoint (46, 55%) was response rate (median 57%, median duration of response 11.1 months). Among the 84 pivotal trials, 38 (45%) had I-A and 32 (38%) had I-B ESCAT targetability score; 24 trials (29%) demonstrated substantial clinical benefit via ESMO-MCBS. Overall, 24 indications (29%) were high-benefit genomic-based cancer treatments.
Conclusions
Fewer than one-third recently approved molecularly-targeted cancer therapies demonstrated high patient benefits. Data often evolve after marketing, but when new cancer treatments are first approved based on exploratory analyses and anti-tumor activity alone, benefit frameworks like ESMO-MCBS and ESCAT can help identify the minority of therapies with the best clinical potential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Funded by the Kaiser Permanente Institute for Health Policy, Dr. Kesselheim and Dr. Avorn’s work also supported by Arnold Ventures.
Disclosure
A. Tibau: Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Training: Lilly, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
1634P - Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Presenter: Jeanne Lena
Session: Poster session 22
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22